© Abivax

French virology company Abivac will receive €390,000 for the development of a polyclonal antibody cocktail to fight Ebola.

© Centogene AG

Orphan diseases diagnostics specialist Centogene AG said it will use the funds for biomarker and CDx development based on its proprietary CentoMD mutation database.

© Bonesupport Holding AB

Swedish orthobiologics company Bonesupport Holding AB announced on Sunday it will go public at Nasdaq Stockholm.

Pipeline of Targovax, © Targovax ASA

Norwegian cancer med developer Targovax ASA has doubled its cash and cash equivalents as of 31 December 2016 by raising NOK200m (€21m) in a private placement of new shares.

German Grünenthal Group has entered into an agreement to acquire the global rights to AstraZeneca’s migraine treatment Zolmitriptan.

Idylla cartridge for BRAF testing; © Biocartis

Belgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.

Fcabs are Fc-region with antigen binding sites (in case of FS118: LAG-3) that are inserted into a full size IgG antibody that binds a secondary target via its Fab part (in case of FS118: PD-L1)  resulting in a bispecific molecule.: PD-L1), © F-Star Biotechnology

German Merck KGaA has secured an option on UK’s F-Star Biotechnology Ltd’s preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.

Cancer tissue, © Bicycle Therapeutics Ltd.

Cambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties. 

UK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch release to a location established in the Union.

Mode of action of allosteric modulation, © Addex Therapeutics Ltd.

Following a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinson’s and ADX71441.